Find information on thousands of medical conditions and prescription drugs.

Idebenone

Idebenone (pronounced eye-deb-eh-known) is a synthetic analog of Coenzyme Q10. more...

 Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Idebenone is similar to CoQ10 in its antioxidant properties. CoQ10 is one of life's most essential biochemicals, hence its title "ubiquinone" (ubi=ubiquitous).

Idebenone is different from Coenzyme Q 10 in one very important way. During a hypoxic (low oxygen) condition, CoQ10 can switch function from an anti-oxidizing to an auto-oxidizing process. This auto-oxidation rapidly produces massive amounts of free radicals which damage the tissues of the body.

Idebenone performs the same functions as CoQ10 without the risk of an auto-oxidation reaction.

Idebenone is said to promote NGF (nerve growth factor) in the brain. It appears to reduce tinnitus (ringing in the ears). Idebenone has also been used in topical applications to treat wrinkles

Read more at Wikipedia.org
• [List your site here Free!]

Takeda Pharmaceutical, Santhera Pharmaceuticals to Collaborate to Develop and Commercialize Idebenone, Drug Candidate for Friedreich's Ataxia
From JCNN News Summaries, 8/5/05

Tokyo, Japan, Aug 4, 2005 - (JCNN) - Takeda Pharmaceutical and Santhera Pharmaceuticals jointly announced on August 3 that the two companies have signed an agreement for Idebenone, (SNT-MC17), a drug candidate for Friedreich's Ataxia developed by Takeda.

Under the terms of the agreement, Takeda will provide data collected from its nonclinical studies in the US and Santhera will proceed with development and apply for approval of the agent in Europe and the US.

In addition, Takeda will pay its partner an upfront payment of 5 million euros as well as development milestones and royalties. Phase III clinical trails will soon start in Europe and the US.

Upon commercialization of the agent, Takeda will market it in Europe while Santhera will handle sales in the US and supply the product.

Friedreich's Ataxia, a spinocerebellar degeneration, is an inherited disease that causes progressive damage to the nervous system, resulting in muscle weakness, speech problems and heart disease.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.

COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group

Return to Idebenone
Home Contact Resources Exchange Links ebay